New publication highlights the benefits and efficacy of spironolactone for dogs with heart failure
A new publication has highlighted the benefits and efficacy of using spironolactone alongside conventional therapy, for the management of heart failure in dogs.
The new publication reveals that there is no increase in the risk of adverse effects, such as hyperkalaemia in the use of spironolactone alongside an ACE inhibitor, in dogs, and there is a significant reduction in the number of deaths due to cardiac disease, renal disease or both cardiac and renal disease.
“This publication further highlights the benefits and safety of using spironolactone alongside an ACEi as part of first-line therapy for canine heart failure,” comments Fraser Broadfoot, MRCVS, small animal product manager at Ceva Animal Health.
“This is now made even easier with the introduction of Cardalis, which contains the leading ACEi, benazepril, and spironolactone at their standard dose in one palatable tablet.”
Cardalis tablets are small, beef flavoured and designed to be administered once a day with food. Each pot contains 30 tablets and there are three sizes available. It should be given as part of standard heart failure therapy as soon as clinical signs, such as exercise intolerance, coughing or dyspnoea, appear.